Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging drugs for migraine prophylaxis and treatment.

Literature DB >> 16926770

Emerging drugs for migraine prophylaxis and treatment.

Marcelo E Bigal¹, Abouch V Krymchantowski.

Abstract

Migraine is a chronic neurologic disorder with heterogeneous characteristics resulting in a range of symptom profiles, burden, and disability. Migraine affects nearly 12% of the adult population in occidental countries, imposing considerable economic and social losses. The pharmacologic treatment of migraine includes preventive and acute strategies. A better understanding of the migraine pathophysiology along with the discovery of novel molecular targets has lead to a growing number of upcoming therapeutic proposals. This review focuses on new and emerging agents for the treatment of migraine.

Entities: Disease

Mesh：

Substances：
Topiramate
Fructose

Year: 2006 PMID： 16926770 PMCID： PMC1785190

Source DB: PubMed Journal: MedGenMed ISSN： 1531-0132

72 in total

1. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors: S D Silberstein
Journal: Neurology Date: 2000-09-26 Impact factor: 9.910

Emerging drugs for migraine prophylaxis and treatment.

1. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

2. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.

3. Immunohistochemical localization of adenosine A1 receptors in human brain regions.

4. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

5. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial.

6. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

7. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.

8. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

9. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: a randomised crossover trial.

10. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain.

1. Pharmacotherapeutics of migraine and the blood-brain barrier: serendipity, empiricism, hope, and hype.

2. Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study.

3. Label-free integrative pharmacology on-target of drugs at the β(2)-adrenergic receptor.